Tamoxifen treated ER+ breast cancers often increase Bcl-2 and Bcl-xL levels, decreasing acute tumor response to Tamoxifen and increasing long-term tamoxifen resistance [35]. The gene discussed is BCL2; the disease is neoplasm.